Costs were calculated using cost function figures compared with usual costs. 5 key findings →
Design: randomized controlled trial Participants: 847 Evidence: high
Full summary, score breakdown and related studies → Original source
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Costs were calculated using cost function figures compared with usual costs. 5 key findings →
Design: randomized controlled trial Participants: 847 Evidence: high
Full summary, score breakdown and related studies → Original source
The inclusion criteria for peer-reviewed English publications from March 2020 to August 2022 consisted of studies related to telehealth services for people living with dementia and their family caregivers and studies conducted during the COVID-19 pandemic. 5 key findings →
Design: randomized controlled trial Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source
The COVID-19 pandemic forced adult day services (ADS) to close and abruptly end in-person services to clients. 5 key findings →
Design: randomized controlled trial Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our pilot study results indicate that it is feasible to recruit, retain, and provide follow-up telephone coaching to older adults after hip fracture. 5 key findings →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The advent of anti-amyloid monoclonal antibody (mAb) therapies represents a paradigm shift in the treatment of Alzheimer's disease (AD), from symptomatic relief to disease modification. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
DeMonte Jr., MD, Joshua Chodosh, MD, MSHS, Xinping Cui, PhD, Stefanie Vassar, MS, Naihua Duan, PhD, and Martin Lee, PhDReduced Health Care Costs Associated With Disease Management for Chronic Heart Failure: A Study Using Three Methods to Examine the Financial Impact of a Heart Failure Disease Management Program Among Medicare Advantage EnrolleesEffects of Nurse Management on the Quality of Heart Failure Care in Minority Communities A Randomized TrialJane E. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Prevalence studies indicate that as many as 50% of older adults experience bothersome pain on a regular basis (Dahlhamer et al., 2018; Galicia-Castillo & Weiner, 2023; Larsson et al., 2017; Lin et al., 2020; Rikard et al., 2023). 5 key findings →
Design: randomized controlled trial Participants: 2,041 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, no significant difference (P > .05) existed between the groups in the scores: (1) for cognitive function on the MMSE or MoCA, (2) for the physiological, psychological, social, and environmental domains and the total score on the WHOQOL-BREF, or (3) for self-efficacy on the GSES scores. 4 key findings →
Design: randomized controlled trial Participants: 112 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors observed that “Our findings showed that nurses provided chronic disease management that was acceptable, feasible and sustainable.” 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Crotty M, Whitehead CH, Wundke R, et al . 4 key findings →
Design: randomized controlled trial Participants: 320 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
He has even given a threshold outlining when the practice of medicine ends versus when the practice of unethical, non–institutional review board approved research begins. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Greater spend on social care (including availability of care home places) was associated with reduced spend in health care, with shorter length of hospital stay and decrease in readmissions. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →